HIV factoid: Approximately half of US diagnosed but untreated HIV carriers have CD4 counts in the 350-500 range; this is the range in which proposed guidelines recommend initiation of antiretroviral treatment while existing guidelines do not.
In other words, patients in the 350-500 range will likely generate a quantum jump in the number of US HIV patients who are treated with such drugs as Atripla and Truvada.
(Source: GILD PJ webcast)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.